Eliquis was the first anti-coagulant to prove that it reduced the risk of death compared to warfarin, which has been the standard of care for preventing strokes in patients with atrial fibrillation, acommonheart rhythm disorder, for seven decades.
Drug safety experts--who understand how even a small increase in risk for acommon problem like heart attacks can have massive effects--need to be there.